Recursion Pharmaceuticals Inc (RXRX) reported a Q3 2025 loss of $0.36 per share, surpassing Wall Street's consensus estimate of $0.38. Revenue remained at $0.0 billion, matching expectations.
The company's performance highlights its operational capabilities within the biotechnology sector, where it leverages automation and artificial intelligence to discover novel medicines. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals employs 840 full-time staff and operates with a market capitalization of $2,008.14 million.
The firm will host an earnings conference call to discuss these results and provide further insights into its business performance. Upcoming earnings reports are scheduled for May 3, 2026, and August 2, 2026, with EPS estimates of $-0.3621 and $-0.3536, respectively.
This update provides insight into Recursion Pharmaceuticals Inc's financial health and operational performance as it continues to advance its clinical programs, including REC-617, an orally bioavailable CDK7 inhibitor targeting advanced solid tumors.